198 related articles for article (PubMed ID: 12649343)
1. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors.
Wirths O; Waha A; Weggen S; Schirmacher P; Kühne T; Goodyer CG; Albrecht S; Von Schweinitz D; Pietsch T
Lab Invest; 2003 Mar; 83(3):429-34. PubMed ID: 12649343
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
3. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
[TBL] [Abstract][Full Text] [Related]
4. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA.
Shou J; Ali-Osman F; Multani AS; Pathak S; Fedi P; Srivenugopal KS
Oncogene; 2002 Jan; 21(6):878-89. PubMed ID: 11840333
[TBL] [Abstract][Full Text] [Related]
5. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
[TBL] [Abstract][Full Text] [Related]
7. Fetal- and tumor-specific regulation of growth hormone receptor messenger RNA expression in human liver.
Zogopoulos G; Albrecht S; Pietsch T; Alpert L; von Schweinitz D; Lefèbvre Y; Goodyer CG
Cancer Res; 1996 Jul; 56(13):2949-53. PubMed ID: 8674047
[TBL] [Abstract][Full Text] [Related]
8. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
9. Beta-catenin expression and mutation in adult and pediatric Wilms' tumors.
Su MC; Huang WC; Lien HC
APMIS; 2008 Sep; 116(9):771-8. PubMed ID: 19024596
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 expression in Wilms tumor and hepatoblastoma.
Toretsky JA; Zitomersky NL; Eskenazi AE; Voigt RW; Strauch ED; Sun CC; Huber R; Meltzer SJ; Schlessinger D
J Pediatr Hematol Oncol; 2001 Nov; 23(8):496-9. PubMed ID: 11878776
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA LINP1 induces tumorigenesis of Wilms' tumor by affecting Wnt/β-catenin signaling pathway.
Zhu KR; Sun QF; Zhang YQ
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5691-5698. PubMed ID: 31298321
[TBL] [Abstract][Full Text] [Related]
12. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
13. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
14. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
15. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors.
López-Terrada D; Gunaratne PH; Adesina AM; Pulliam J; Hoang DM; Nguyen Y; Mistretta TA; Margolin J; Finegold MJ
Hum Pathol; 2009 Jun; 40(6):783-94. PubMed ID: 19200579
[TBL] [Abstract][Full Text] [Related]
16. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
17. Association of E2F3 expression with clinicopathological features of Wilms' tumors.
An Q; Wang Y; An R; Li Y; Yao T; Zhai B; Sun X
J Pediatr Surg; 2013 Nov; 48(11):2187-93. PubMed ID: 24210184
[TBL] [Abstract][Full Text] [Related]
18. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
19. Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma.
Albrecht S; Hartmann W; Houshdaran F; Koch A; Gärtner B; Prawitt D; Zabel BU; Russo P; Von Schweinitz D; Pietsch T
Int J Cancer; 2004 Sep; 111(4):627-32. PubMed ID: 15239143
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.
Yamada S; Ohira M; Horie H; Ando K; Takayasu H; Suzuki Y; Sugano S; Hirata T; Goto T; Matsunaga T; Hiyama E; Hayashi Y; Ando H; Suita S; Kaneko M; Sasaki F; Hashizume K; Ohnuma N; Nakagawara A
Oncogene; 2004 Aug; 23(35):5901-11. PubMed ID: 15221005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
